Valuation: C4 Therapeutics, Inc.

Market Cap 518M 444M 415M 381M 716M 49.5B 728M 4.9B 1.92B 24.83B 1.94B 1.9B 82.09B P/E 2026 *
-4.82x
P/E 2027 * -4.34x
Enterprise Value 518M 444M 415M 381M 716M 49.5B 728M 4.9B 1.92B 24.83B 1.94B 1.9B 82.09B EV / Sales 2026 *
24.2x
EV / Sales 2027 * 25.2x
Free-Float
99.17%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: C4 Therapeutics, Inc.

1 day+0.72%
1 week+7.95%
Current month+20.98%
1 month+14.09%
3 months+35.37%
6 months+98.58%
Current year+120.42%
1 week 3.9
Extreme 3.895
4.38
1 month 3.36
Extreme 3.36
4.38
Current year 1.69
Extreme 1.6901
5.17
1 year 1.69
Extreme 1.6901
5.17
3 years 1.06
Extreme 1.06
11.88
5 years 1.06
Extreme 1.06
51.21
10 years 1.06
Extreme 1.06
51.21
Manager TitleAgeSince
Chief Executive Officer 55 02/10/2020
Director of Finance/CFO 49 18/09/2023
Chief Tech/Sci/R&D Officer 56 28/10/2024
Director TitleAgeSince
Director/Board Member 74 01/12/2015
Director/Board Member 55 14/09/2020
Director/Board Member 55 16/03/2022
Date Insider Type Main position Quantity % Market Cap.
7/10/26 A Fiscal year

Chief Technology Officer

22,722 0.0206%
7/1/26 A Free

Director

3,341 0.0030%
7/1/26 A Free

Founder

2,650 0.0024%
Change 5-day change 1-year change 3-year change Capi.($)
+0.72%+7.95%+52.54%+30.34% 514M
+2.37%+2.30%+3.39%+22.74% 48.63B
-0.62%+4.58%+487.47%+624.71% 46.3B
+2.09%+4.96%+20.59%+95.21% 41.97B
+3.85%+3.13%+29.60%+16.50% 39.51B
-0.72%-3.91%+17.87%+47.98% 31.75B
+3.04%+1.89%+31.62%+143.62% 16.48B
+4.33%+1.63% - - 16.34B
+1.44%+1.52%+4.22%+31.00% 14B
+3.87%+1.98%+82.99%+45.80% 13.33B
Average +2.04%+1.74%+81.14%+117.54% 26.88B
Weighted average by Cap. +1.85%+0.98%+107.13%+156.95%

Financials

2026 *2027 *
Net sales 21.42M 18.38M 17.16M 15.75M 29.61M 2.05B 30.1M 202M 79.29M 1.03B 80.45M 78.7M 3.4B 20.54M 17.62M 16.45M 15.09M 28.39M 1.96B 28.85M 194M 76.02M 985M 77.12M 75.45M 3.26B
Net income -115M -98.77M -92.23M -84.62M -159M -11.01B -162M -1.09B -426M -5.52B -432M -423M -18.25B -150M -129M -120M -110M -207M -14.32B -210M -1.42B -555M -7.18B -563M -550M -23.75B
Net Debt - -
Logo C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Employees
104
Date Price Change Volume
19/08/26 $4.210 +0.72% 2,847,921
18/08/26 $4.180 -1.99% 2,878,764
17/08/26 $4.265 +0.59% 2,086,808
14/08/26 $4.240 +3.92% 3,399,046
13/08/26 $4.080 +4.62% 3,726,050
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.210USD
Average target price
13.33USD
Spread / Average Target
+216.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CCCC Stock